{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3"},{"groupId":"OG001","value":"82.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"344"}],"units":"Participants"}],"description":"Disease control rate based on investigator assessments according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD).","groups":[{"description":"Drug: Durvalumab IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.","id":"OG000","title":"Durvalumab + Gemcitabine + Cisplatin"},{"description":"Drug: Placebo IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.","id":"OG001","title":"Placebo + Gemcitabine + Cisplatin"}],"paramType":"NUMBER","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter. Assessed up to maximum of approximately 27 months.","title":"Disease Control Rate (DCR) - Overall","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}